Zepbound is the preferred weight loss medicine vs. Wegovy and has consistently beaten the latter in U.S. weekly prescriptions ...

Shares of the company, which once boasted of media mogul Oprah Winfrey as one of its top shareholders, slumped 40% in ...

As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...

Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...

Another was a looming late-stage clinical trial of a closely watched pipeline drug that's loaded with potential. For a ...

Hims & Hers Health Inc has reiterated its 2025 revenue forecast after posting better-than-expected sales for the first ...

Gov. Glenn Youngkin saved about $7 million in state funds and $40 million in federal funds by vetoing a lower body-mass index ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Zepbound, Lilly’s obesity drug, has overtaken Novo’s equivalent, Wegovy, in the US and now commands over 50 per cent of the ...

GLP-1 medications like Wegovy and Zepbound curb hunger, but can also cut out important nutrients from your diet. Here are ...